DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Orchid Pharma Limited — Outcome of Board Meeting

NSE 2 hrs ago·14 Aug 2026, 1:13 pm

Orchid Pharma

Orchid Pharma has informed the stock exchange about its financial results for the period ending March 31, 2026. This filing is a standard regulatory requirement that allows the company to disclose its performance metrics to the public and regulators.

For investors, this update is important as it provides the latest data on the company's operational health. It offers a snapshot of its financial position, helping shareholders assess the firm's current standing before the official release of detailed reports.

Investors should watch for the detailed financial statements to be released shortly. These documents will provide a deeper analysis of the company's revenue, expenses, and profitability, which are key factors in evaluating the stock's future performance.